Building Life

Founded in 2013, Arcturus is a leader in RNA medicines.

Placeholder

Arcturus Therapeutics

  • Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR TherapeuticREAD MORE
  • Takeda Pharmaceuticals logoTakeda Pharmaceuticals entered into collaboration with Arcturus Therapeutics to develop RNA-based therapeutics for the treatment of NASH.READ MORE
  • Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.READ MORE

Proprietary Technologies

UNA and LUNAR™ have the Potential to Revolutionize RNA Medicines

TRANSPORTERS RECEPTORS ANTIBODIES ENZYMES TALEN GPCR’S HORMONES CHAPERONES CAR-T CRISPR
Trans-membrane Proteins Secreted Proteins Intracellular Proteins Engineered Antigens Engineered Nucleases
READ MORE

RNA Medicines

  • Antisense RNA
    Antisense RNA works by binding to messenger RNA (mRNA) and physically preventing the cell from translating the mRNA into protein. READ MORE
  • Gene Editing
    Human DNA has roughly 20 000 genes. Each gene contains the code needed to make one or more proteins. READ MORE
  • MicroRNA
    MicroRNA medicines can be used to treat complex diseases like cancer that are caused by many different malfunctioning proteins. READ MORE
  • mRNA
    Messenger RNA (mRNA) therapeutics can treat diseases caused by a lack of protein, or by defective proteins, such as Duchenne muscular dystrophy and cystic fibrosis. READ MORE
  • RNA
    RNA medicines can target any gene or protein in humans and so can be used to treat diseases that cannot be treated by conventional drugs such as small molecules and biologics. READ MORE
  • RNAi
    RNA interference (RNAi) is a natural mechanism used by the body to turn genes off without permanently changing DNA. READ MORE
  • siRNA
    Small interfering RNA (siRNA) medicines can treat viral infections like hepatitis B and diseases like Huntington’s disease that are caused by malfunctioning proteins. READ MORE

Pipeline

name

LUNAR-OTC

indication
OTC Deficiency
api
mUNA

INTERNAL mUNA PROGRAMS

PRECLINICAL

name

LUNAR-HBV

indication
Hepatitis B
api
siUNA

PRECLINICAL

name

Arbutus, ARB-1467

indication
Hepatitis B
api
siUNA

LICENSED PROGRAMS

CLINICAL

News & Events

  • May 30, 2017

    Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic

    • September 12 2017
    • 0
    read more
  • August 23, 2017

    Pictures by Ernst and Young (Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego)

    • August 23 2017
    • 0
    read more
  • August 9, 2017

    Arcturus Therapeutics in the list of Cystic Fibrosis Key Companies

    • August 9 2017
    • 0
    read more
  • July 13, 2017

    Arcturus Therapeutics Inc. is Listed in the Key Players List; Involved in Non Alcoholic Steatohepatitis Pipeline (NASH)

    • July 13 2017
    • 0
    read more
  • July 7, 2017

    The Korea Herald News on Arcturus Therapeutics Inc.

    • July 7 2017
    • 0
    read more
  • July 6, 2017

    Union Tribune article on Arcturus Therapeutics Inc.

    • July 6 2017
    • 0
    read more
  • June 22, 2017

    GEN article on Arcturus Therapeutics Inc.

    • June 22 2017
    • 0
    read more
  • June 20, 2017

    Xconomy article on Arcturus Therapeutics, Inc.

    • June 20 2017
    • 0
    read more
  • June 19, 2017

    San Diego Business Journal article on Arcturus Therapeutics Inc.

    • June 19 2017
    • 0
    read more